HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Winter, W. E. Search for Related Content PubMed PubMed Citation Articles by Winter, W. E. Related Collections Evidence Based Laboratory Medicine and Test Utilization Endocrinology and Metabolism

A Rosetta Stone for Insulin Treatment: Self-Monitoring of Blood Glucose

¹ University of Florida, Department of Pathology, Immunology and Laboratory Medicine, Box 100275, Gainesville, FL 32610-0275, Fax 352-846-2149, E-mail winter@pathology.ufl.edu

The first 300 words of the full text of this article appear below.

In the daily management of type 1 diabetes, self-monitoring of blood glucose (SMBG) is the recommended glycemic monitor, or "Rosetta stone", that enables improved glycemic control (1). By measuring real-time glucose, informed patients can modify their diabetes management acutely or prospectively to sustain glucose in a narrow range near normal. A recent study from the Veterans Administration demonstrated improved glycemic control with lowered hemoglobin A_1c in patients with insulin-treated type 2 diabetes who performed SMBG (2). A wide range of insulins is now available with various durations of action that can help to improve glycemic control. The greatest therapeutic advances entail the use of recombinant DNA-engineered insulin analogs. Novel insulins such as lyspro-insulin [lysine(B28), proline(B29)] have a very rapid onset of action (15–30 min), peak effect (1–2 h), and limited overall duration of action (3–4 h), whereas glargine (^A-Gly-30^Ba-L-Arg-30^Bh-L-Arg-human) has no peak and a duration of action of 24 h or longer.

Maintaining blood glucose at or very near the normal range decreases the frequency of new-onset microvascular complications and delays the progression of established microvascular complications in both type 1 and type 2 diabetes (3)(4)(5). In non-insulin-treated patients, before 2002 there were few data to suggest that SMBG improved clinical outcome (6). However a recent study from France found that SMBG lowered hemoglobin A_1c in monitored, non-insulin-treated type 2 diabetes (7), as did a study from Germany (8).

Accurate and precise blood glucose measurements are no doubt helpful and important to achieve optimal diabetic care (9). However, unless patients alter their care (e.g., acute adjustments in diet, exercise, or insulin dosing) in response to the real-time blood glucose or in anticipation of changes in . . . [Full Text of this Article]